Soft tissue matrix characterization using stretched exponential relaxation modeling
View Patent ↗A process for more sensitive characterization of tissue composition for generating a quantitative MRI (qMRI) map and corresponding delta analysis. Intervertebral disc degeneration (IVDD), resulting in the depletion of hydrophilic glycosaminoglycans (GAGs) located in the nucleus pulposus (NP), can lead to debilitating neck and back pain. Magnetic Resonance Imaging (MRI) is a promising means of IVD assessment due to the correlation between GAG content and MRI relaxation values. T1 and T2 relaxation data were obtained from healthy cervical IVDs, and relaxation data was modeled using both conventional and stretched exponential (SE) decays. Normalized histograms of the resultant quantitative MRI (qMRI) maps were fit with stable distributions. SE models fit relaxation behavior with lower error compared to monoexponential models, indicating anomalous relaxation behavior in healthy IVDs. SE model parameters T1 and T1 increased with IVD segment, while conventional monoexponential measures did not vary. The improved model fit and correlation between both SE T1 and T1 with IVD level suggests these parameters are more sensitive biomarkers for detection of GAG content variation.
1. A method for detecting intervertebral disc degeneration (IVDD) in a subject comprising the steps of:
measuring a T1 ρSE relaxation time of glycosaminoglycan (GAG) in a disc of the subject using magnetic resonance imaging;
comparing the measured T1 ρSE relaxation time to a baseline T1 ρSE relaxation time indicative of healthy tissue;
measuring a α T1 ρ relaxation time of GAG in the disc of the subject using magnetic resonance imaging;
comparing the determined α T1 ρ relaxation time to a baseline α T1 ρ relaxation time indicative of healthy tissue; and
determining a decrease in the GAG content in the disc of the subject based on results of the comparing step for both the T1 ρSE relaxation time to a baseline T1 ρSE relaxation time and the α T1 ρ relaxation time to a baseline α T1 relaxation time, wherein a decrease in the GAG content in the disc of a subject is indicative of IVDD in the subject.
2. The method according to claim 1 wherein T1 ρSE relaxation time of GAG is measured in the nucleus pulposus (NP) of the subject using magnetic resonance imaging and wherein a decrease in the GAG content in the NP of a subject is indicative of IVDD in the subject.
3. The method according to claim 1 wherein the magnetic resonance imaging is processed using a pixel-by-pixel method.
4. A method of monitoring progress of intervertebral disc degeneration (IVDD) in a subject comprising the steps of:
measuring a baseline T1 ρSE relaxation time of glycosaminoglycan (GAG) in a nucleus pulposus (NP) of a subject using magnetic resonance imaging;
measuring one or more additional T1 ρSE relaxation times;
comparing at least one of the one or more additional T1 ρSE relaxation times measured to the baseline value of the T1 ρSE relaxation time;
measuring a baseline α T1 ρ relaxation time of GAG in the NP of the subject using magnetic resonance imaging;
measuring one or more additional α T1 ρ relaxation times;
comparing at least one of the one or more additional α T1 ρ relaxation times measured to the baseline value of the α T1 ρ relaxation time; and
determining a decrease in the GAG content in the NP of the subject based on results of the comparing step for both the T1 ρSE relaxation time to a baseline T1 ρSE relaxation time and the α T1 ρ relaxation time to a baseline α T1 relaxation time, wherein a decrease in the GAG content in the NP of a subject is indicative of continued IVDD in the subject.
5. A method of evaluating the effectiveness of an intervertebral disc degeneration (IVDD) treatment comprising the steps of:
measuring a baseline T1 ρSE relaxation time of glycosaminoglycan (GAG) in a nucleus pulposus (NP) of a subject prior to or upon initiation of the treatment using magnetic resonance imaging;
measuring a baseline α T1 ρ relaxation time of the GAG in the NP of a subject prior to or upon initiation of the treatment using magnetic resonance imaging;
initiating the treatment of the IVDD in the subject;
measuring one or more additional T1 ρSE relaxation times after initiation of the treatment;
comparing at least one of the one or more additional T1 ρSE relaxation times measured after initiation of the treatment to the baseline value of the T1 ρSE relaxation time;
measuring one or more additional α T1 ρ relaxation times after initiation of the treatment;
comparing at least one of the one or more additional α T1 ρ relaxation times measured after initiation of the treatment to the baseline value of the α T1 ρ relaxation time; and
determining a change in the GAG content in the NP of the subject based on results of the comparing step for both the T1 ρSE relaxation time to a baseline T1 ρSE relaxation time and the α T1 ρ relaxation time to a baseline α T1 relaxation time, wherein an increase in GAG content is indicative of treatment effectiveness.
6. The method according to claim 5 wherein the magnetic resonance imaging is processed using a pixel-by-pixel method.
7. A method for detecting intervertebral disc degeneration (IVDD) in a subject comprising the steps of:
measuring a α T1 ρ relaxation time of glycosaminoglycan (GAG) in a disc of the subject using magnetic resonance imaging;
comparing the measured α T1 ρ relaxation time to a baseline T1 ρSE relaxation time indicative of healthy tissue; and
determining a decrease in the GAG content in the disc of the subject based on results of the comparing step, wherein a decrease in the GAG content in the disc of a subject is indicative of IVDD in the subject.
8. A method for detecting intervertebral disc degeneration (IVDD) in a subject comprising the steps of:
measuring a α T1 ρ relaxation time of glycosaminoglycan (GAG) in a nucleus pulposus (NP) of the subject using magnetic resonance imaging;
comparing the determined α T1 ρ relaxation time to a baseline α T1 ρ relaxation time indicative of healthy tissue; and
determining a decrease in the GAG content in the NP of the subject based on results of the comparing step, wherein a decrease in the GAG content in the NP of a subject is indicative of IVDD in the subject.
9. The method according to claim 8 wherein the magnetic resonance imaging is processed using a pixel-by-pixel method.
10. A method of monitoring progress of intervertebral disc degeneration (IVDD) in a subject comprising the steps of:
measuring a baseline α T1 ρ relaxation time of glycosaminoglycan (GAG) in a nucleus pulposus (NP) of a subject using magnetic resonance imaging;
measuring one or more additional α T1 ρ relaxation times;
comparing at least one of the one or more additional α T1 ρ relaxation times measured to the baseline value of the α T1 ρ relaxation time; and
determining progress of intervertebral disc degeneration based on results of said comparing step.
11. A method of evaluating the effectiveness of an intervertebral disc degeneration (IVDD) treatment comprising the steps of:
measuring a baseline α T1 ρ relaxation time of glycosaminoglycan (GAG) in a nucleus pulposus (NP) of a subject prior to or upon initiation of the treatment using magnetic resonance imaging;
initiating the treatment of the IVDD in the subject;
measuring one or more additional α T1 ρ relaxation times after initiation of the treatment;
comparing at least one of the one or more additional α T1 ρ relaxation times measured after initiation of the treatment to the baseline value of the α T1 ρ relaxation time; and
determining an effectiveness of the treatment based on results of the comparing step.
12. The method according to claim 11 wherein the magnetic resonance imaging is processed using a pixel-by-pixel method.